2019
Proposal for Value-Based, Tiered Reimbursement for Tumor Biomarker Tests to Promote Innovation and Evidence Generation.
Dinan MA, Lyman GH, Schilsky RL, Hayes DF. Proposal for Value-Based, Tiered Reimbursement for Tumor Biomarker Tests to Promote Innovation and Evidence Generation. JCO Precision Oncology 2019, 3: 1-10. PMID: 35100733, DOI: 10.1200/po.19.00210.Peer-Reviewed Original ResearchTumor biomarker testsClinical utilityBiomarker testsFormal cost-effectiveness analysisHigh-level evidenceLow-level evidenceHealth care dollarsPrecision cancer careCost-effectiveness analysisCancer careEffective therapyCancer precision medicineTreatment decisionsTreatment selectionIneffective treatmentPoor reimbursement
2016
ONCOLOGISTS’ BARRIERS AND FACILITATORS FOR ONCOTYPE DX USE: QUALITATIVE STUDY
Roberts MC, Bryson A, Weinberger M, Dusetzina SB, Dinan MA, Reeder-Hayes K, Wheeler SB. ONCOLOGISTS’ BARRIERS AND FACILITATORS FOR ONCOTYPE DX USE: QUALITATIVE STUDY. International Journal Of Technology Assessment In Health Care 2016, 32: 355-361. PMID: 27958190, PMCID: PMC6526532, DOI: 10.1017/s026646231600060x.Peer-Reviewed Original ResearchConceptsAdjuvant chemotherapy decisionsBreast cancer patientsOncotype DXTreatment decisionsCancer patientsChemotherapy decisionsHormone receptor-positive breast cancer patientsClinical practiceReceptor-positive breast cancer patientsPositive breast cancer patientsOncotype DX useUnited States guidelinesProfiling testsEligible womenSurgical oncologistsCancer careClinical guidelinesModifiable barriersOncologistsMulti-level factorsPatientsThematic saturationPhone interviewsIntermediate scoresQualitative study